文献速递眼底病与葡萄膜炎

光学相干断层扫描解剖与时间生物标志物在葡萄膜炎性黄斑水肿中的应用

Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular Edema.
PubMed 文献 · Am J Ophthalmol · 2021-11-03

该研究为两项3期临床试验的事后分析,纳入198例非感染性葡萄膜炎患者,其中134例接受脉络膜上腔注射CLS-TA,64例接受假注射。结果显示,基线椭圆体带完整性和中心凹囊样间隙或视网膜下液的存在可预测更好的治疗反应;在CLS-TA治疗眼中,中心亚区厚度改善早于最佳矫正视力改善。

要点

  • 基线椭圆体带完整者24周BCVA改善11.9字母,优于部分破坏者的9.4字母(P=0.006)。
  • 基线有中心凹囊样间隙或视网膜下液者24周BCVA改善更多(分别为13.7或17.2字母)。
  • CLS-TA治疗眼中心亚区厚度3周达90%最大改善,而BCVA至9周才达90%最大反应。

核心结论

  • 治疗前椭圆体带完整性和中心凹囊样间隙或视网膜下液的存在可预测非感染性葡萄膜炎眼对治疗的反应改善。
  • 在CLS-TA治疗眼中,纵向模型显示中心亚区厚度改善早于最佳矫正视力改善。

研究设计与样本

  • 研究设计为两项3期临床试验事后分析的临床队列研究。
  • 共纳入198例非感染性葡萄膜炎患者,其中134例接受脉络膜上腔注射CLS-TA,64例接受假注射;两组分别有12.9%和72%接受挽救治疗。

主要发现

  • 基线时,平均最佳矫正视力随中心亚区椭圆体带完整性每 ordinal 下降而逐渐恶化。
  • 基线椭圆体带正常眼24周BCVA变化为11.9字母,优于基线椭圆体带有某种程度破坏眼的9.4字母(P=0.006)。
  • 基线有中心凹囊样间隙眼24周BCVA改善13.7字母,优于无此表现眼的5.5字母(P=0.012)。
  • 基线有视网膜下液眼24周BCVA改善17.2字母,优于无此表现眼的9.5字母(P<0.001)。
  • CLS-TA治疗眼纵向模型显示中心亚区厚度第3周达90%最大改善,而BCVA至第9周才达90%最大反应;第4周中心亚区厚度降低≥50 µm眼24周BCVA改善14.6字母,优于无此早期反应眼的6.5字母(差异P=0.006)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the relationship between best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) features in noninfectious uveitis (NIU)-related macular edema. DESIGN: Clinical cohort study from post hoc analysis of 2 phase 3 clinical trials. METHODS: Correlation and longitudinal treatment analyses were performed. Of 198 patients with NIU, 134 received suprachoroidal CLS-TA (proprietary formulation of a triamcinolone acetonide injectable suspension), and 64 received sham, with 12.9% and 72%, respectively, receiving rescue therapy. RESULTS: At baseline, mean BCVA progressively worsened with each ordinal drop in central subfield ellipsoid zone (EZ) integrity. Eyes with normal baseline EZ experienced greater 24-week change in BCVA versus those with some degree of baseline EZ disruption (11.9 vs 9.4 letters, P = .006). In contrast, eyes with baseline central subfield cystoid spaces and/or subretinal fluid showed more improvement (13.7 or 17.2 letters, respectively) at 24 weeks, versus those without such findings (5.5 [P = .012] or 9.5 letters [P < .001], respectively). Longitudinal modeling for CLS-TA-treated eyes showed that central subfield thickness (CST) reached 90% of maximal improvement by week 3, whereas 90% maximal response in BCVA was not reached until week 9. CLS-TA-treated eyes that showed CST reduction of ≥50 µm at 4 weeks experienced a greater 24-week improvement in BCVA versus those without such an early response (14.6 vs 6.5 letters, P = .006 for difference). CONCLUSIONS: Pretreatment EZ integrity and the presence of central subfield cystoid spaces or subretinal fluid each predict improved therapeutic response to treatment in eyes with NIU. In CLS-TA treated eyes, longitudinal modeling shows CST improvement preceding BCVA improvement.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ciulla TA, Kapik B, Barakat MR, et al. Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular Edema. Am J Ophthalmol. 2021. PMID: 34740628. doi:10.1016/j.ajo.2021.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。